At What Stage Does Dialysis Start for Kidney Disease? A Stage-by-Stage Guide

Dialysis typically starts when kidney function falls to about 10–15 percent of normal, which corresponds to stage 5 chronic kidney disease (CKD) with an estimated glomerular filtration rate (eGFR) below 15 mL/min/1.73 m². Most patients begin treatment before that threshold, when eGFR drops to roughly 5–10 mL/min/1.73 m² and symptoms or lab abnormalities appear. In practice, the decision rests less on a single number than on a combination of eGFR trajectory, uremic symptoms, fluid overload, and potassium or acid-base control that no longer responds to medication and diet. A minority start earlier for specific complications.

The Mechanism: Why eGFR Below 15 mL/min/1.73 m² Marks the Line

The kidneys filter roughly 180 liters of plasma per day. When nephron mass falls below about 10 percent, the surviving nephrons cannot clear nitrogenous waste, balance potassium, or excrete acid fast enough to keep pace with normal metabolism. This is the mechanistic reason dialysis becomes necessary, not an arbitrary cutoff.

The key concept is the "sink" effect. In early and middle CKD, remaining nephrons compensate by hyperfiltration, meaning each surviving glomerulus filters more than its share. That compensation is why a person can lose 70–80 percent of kidney function and still show a normal serum creatinine. Once the compensatory reserve is exhausted, waste products accumulate rapidly.

Two solutes drive the decision: urea and potassium. Urea itself is relatively benign at moderate levels, but its accumulation tracks with the retention of hundreds of other solutes that cause uremic symptoms such as fatigue, nausea, and itching. Potassium is the safety-critical one; above roughly 6.0 mmol/L, the risk of fatal cardiac arrhythmia rises sharply.

In plain terms: dialysis replaces the filtering work that fewer than one in ten original nephrons can no longer perform.

The threshold of eGFR below 15 mL/min/1.73 m² defining stage 5 comes from the NKF-KDOQI classification system; the 2012 KDIGO guidelines, updated in 2024, retained this same structure. It is a staging convention, not an automatic trigger for treatment.

The Stage-by-Stage Timeline: From Diagnosis to First Treatment

The table below reconciles the staging thresholds with typical timing to dialysis. Note that eGFR decline is not linear; it accelerates as nephron loss compounds.

The time estimates assume an average eGFR decline of 2–5 mL/min/1.73 m² per year, which is typical for diabetic kidney disease without aggressive intervention. Patients with rapidly progressive glomerulonephritis can traverse multiple stages in months, while some stable patients with eGFR in the low teens never progress to dialysis within their lifetime.

The critical reconciliation: stage 5 begins at eGFR below 15, but dialysis usually starts at eGFR 5–10. The gap between 15 and 10 is the "prepare, don't yet dialyze" window, where access is created and education happens.

The "Early Start" Myth: Why eGFR 20 Is Usually Too Soon

A common misconception is that starting dialysis earlier protects the kidneys. The evidence says otherwise. The landmark IDEAL trial, published in the New England Journal of Medicine in 2010 by Cooper and colleagues, randomized patients to start dialysis early (eGFR 10–14) versus late (eGFR 5–7). Early initiation produced no survival benefit and slightly worse quality-of-life scores.

The mechanism is straightforward. Dialysis itself imposes a physiologic cost: intermittent fluid shifts, infection risk from catheters, and accelerated loss of residual kidney function. Residual function matters; patients who retain urine output have better survival and easier fluid management. Starting early sacrifices that residual function for no measurable gain.

The 2015 European Renal Best Practice guideline reinforced this with a "watch and wait" position for asymptomatic patients, even below eGFR 10. The unifying principle: treat patients, not numbers.

Symptoms and Labs That Trigger the Start

The decision to initiate hinges on clinical signals more than raw eGFR. These include refractory hyperkalemia, fluid overload unresponsive to diuretics, uremic pericarditis, and encephalopathy. Each signal carries a specific threshold.

Per the 2021 KDIGO controversies conference and standard nephrology practice, initiation is generally indicated when any of the following appear:

• Uremic symptoms: nausea, vomiting, anorexia, weight loss, or persistent fatigue that impairs daily function
• Refractory hyperkalemia above 6.0 mmol/L despite dietary and medication management
• Fluid overload with pulmonary edema or hypertension not controlled by diuretics
• Metabolic acidosis with serum bicarbonate persistently below 18 mmol/L
• Uremic pericarditis or encephalopathy, which are urgent indications regardless of eGFR

The last two are emergencies. A patient can be at eGFR 12 with no symptoms and wait, or at eGFR 14 with pericarditis and start within days.

Choosing the Modality: Hemodialysis Versus Peritoneal Dialysis

Once initiation is decided, the modality choice affects timing. Hemodialysis via an arteriovenous fistula requires 6–12 weeks to mature after surgical creation, so access planning starts at stage 4. Peritoneal dialysis can begin sooner after catheter placement, typically within 2 weeks.

Preemptive kidney transplant, performed before dialysis is ever needed, offers the best outcomes. Candidates with a living donor may receive a transplant at eGFR 15–20, before dialysis initiation becomes necessary.

Special Populations: Where the Numbers Shift

The eGFR 5–10 initiation range is a general benchmark, not a universal rule. Several groups deviate.

Elderly patients with multiple comorbidities often start later, or choose conservative kidney management (no dialysis) entirely. A 2020 study in the Journal of the American Society of Nephrology found that among patients over 75, conservative management produced survival comparable to dialysis for those with high comorbidity scores. The decision becomes about quality of life, not renal numbers.

Diabetic patients may show earlier uremic symptoms at the same eGFR, because diabetic gastroparesis and neuropathy mimic uremia. Nephrologists often wait for symptom clarity rather than pull the trigger at a specific number.

Pregnant patients with advanced CKD require individualized planning because dialysis during pregnancy alters dosing and timing considerably, and initiation often occurs at higher eGFR to protect fetal outcomes.

Children follow different growth-based thresholds. Pediatric nephrology societies may initiate dialysis when growth falters or eGFR falls below 10, whichever comes first.

Practical Preparation: What to Do in Stages 3b and 4

Because access creation takes months, preparation must start well before symptoms force the issue. Patients and clinicians who plan ahead avoid emergency catheter dialysis, which carries higher infection and mortality risk than a matured fistula.

Concrete positive actions for the stage 3b to 4 window:

• Ask for a nephrology referral if eGFR is below 30 and not already under specialist care
• Get vein mapping of both arms at stage 4, so a fistula can be planned without delay
• Attend a modality education class to compare in-center hemodialysis, home hemodialysis, and peritoneal dialysis
• Request a transplant evaluation early, ideally at eGFR 20, because waitlist times can stretch years
• Review all medications with a pharmacist to remove nephrotoxic drugs such as NSAIDs and certain contrast agents
• Track potassium and bicarbonate at each visit; trends matter more than single values

Avoid the trap of waiting for symptoms. By the time nausea and fatigue become disabling, the patient may need urgent dialysis through a temporary catheter, which is the inferior path.

Limits of the Numbers: What the Thresholds Cannot Predict

The eGFR-based thresholds are population averages. Individual trajectories vary widely, and no equation captures every patient. The CKD-EPI 2021 creatinine equation, which removed the race coefficient, performs differently across body compositions; very muscular or very frail patients may have eGFR estimates that mislead by 10–20 mL/min/1.73 m².

A counterintuitive caveat: a patient's eGFR can appear stable for years and then plummet in months, especially with superimposed acute kidney injury from dehydration, contrast, or infection. An eGFR that drops by more than 25 percent within a year warrants urgent re-evaluation, because it predicts faster progression to dialysis.

The broader limitation is that thresholds answer "when" only for populations. For any single patient, the answer comes from combining the number, the trend, the symptoms, and the labs. Nephrologists frequently start dialysis at eGFR 12 in one patient and hold at eGFR 7 in another, based on those factors. The guideline range of 5–10 mL/min/1.73 m² with symptoms remains the honest summary; anyone claiming a single hard number has oversimplified the mechanism.